<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35570863</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">1930-0433</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>17</Volume>
            <Issue>7</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jul</Month>
            </PubDate>
          </JournalIssue>
          <Title>Radiology case reports</Title>
          <ISOAbbreviation>Radiol Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Plexiform neurofibromatosis with peripheral malignant nerve sheath tumor and scoliosis - more surveillance imaging needed?</ArticleTitle>
        <Pagination>
          <StartPage>2388</StartPage>
          <EndPage>2393</EndPage>
          <MedlinePgn>2388-2393</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.radcr.2022.03.111</ELocationID>
        <Abstract>
          <AbstractText>Malignant peripheral nerve sheath tumors (MPNSTs) are rare but aggressive neoplasms associated with neurofibromatosis type 1. Specifically, children with deep plexiform neurofibromas are 18 times more likely to develop MPNSTs compared to the general population. However, there is currently no standard surveillance imaging protocol for children diagnosed with deep plexiform neurofibromatosis. We present a case of a boy with neurofibromatosis type 1 and scoliosis, who later developed MPNST. This case highlights the need for more frequent surveillance imaging and the challenges of diagnosing MPNST in a patient with scoliosis. In order to facilitate early detection of malignant transformation, we suggest annual surveillance MR imaging for patients known to have deep plexiform neurofibromatosis.</AbstractText>
          <CopyrightInformation>© 2022 The Authors. Published by Elsevier Inc. on behalf of University of Washington.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kamaludin</LastName>
            <ForeName>Siti Nurhazwani</ForeName>
            <Initials>SN</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Sabah Women and Children's Hospital, Kota Kinabalu, 88400, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yusuf</LastName>
            <ForeName>Marlina</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Sabah Women and Children's Hospital, Kota Kinabalu, 88400, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nicholas</LastName>
            <ForeName>Warren Erwin</ForeName>
            <Initials>WE</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Sabah Women and Children's Hospital, Kota Kinabalu, 88400, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Paul</LastName>
            <ForeName>Aaron</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Orthopedics, Queen Elizabeth Hospital, Kota Kinabalu, 88200, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Teh</LastName>
            <ForeName>Yong Guang</ForeName>
            <Initials>YG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Radiology, Sabah Women and Children's Hospital, Kota Kinabalu, 88400, Malaysia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Medicine &amp; Health Sciences, Universiti Malaysia Sabah, Kota Kinabalu, Sabah 88400, Malaysia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Radiol Case Rep</MedlineTA>
        <NlmUniqueID>101467888</NlmUniqueID>
        <ISSNLinking>1930-0433</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Case report</Keyword>
        <Keyword MajorTopicYN="N">MPNST, malignant peripheral nerve sheath tumor</Keyword>
        <Keyword MajorTopicYN="N">NF-1, neurofibromatosis type 1</Keyword>
        <Keyword MajorTopicYN="N">Neurofibromatosis type I</Keyword>
        <Keyword MajorTopicYN="N">Peripheral malignant peripheral sheath tumor</Keyword>
        <Keyword MajorTopicYN="N">Plexiform neurofibroma</Keyword>
        <Keyword MajorTopicYN="N">Scoliosis</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>3</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35570863</ArticleId>
        <ArticleId IdType="pmc">PMC9096456</ArticleId>
        <ArticleId IdType="doi">10.1016/j.radcr.2022.03.111</ArticleId>
        <ArticleId IdType="pii">S1930-0433(22)00283-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005;65(2):205–211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16043787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rasmussen SA, Yang Q, Friedman JM. Mortality in neurofibromatosis 1: an analysis using US death certificates. Am J Hum Genet. 2001;68(5):1110–1118.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1226092</ArticleId>
            <ArticleId IdType="pubmed">11283797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zöller M, Rembeck B, Akesson HO, Angervall L. Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta dermato-venereologica. 1995;75(2):136–140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7604643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Research. 2002;62:1573–1577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11894862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miettinen MM, Antonescu CR, Fletcher CD, Kim A, Lazar AJ, Quezado MM, et al.  Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1—a consensus overview. Hum Pathol. 2017;67:1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5628119</ArticleId>
            <ArticleId IdType="pubmed">28551330</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Raedt T, Brems H, Wolkenstein P, Vidaud D, Pilotti S, Perrone F, et al.  Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003;72(5):1288–1292.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1180281</ArticleId>
            <ArticleId IdType="pubmed">12660952</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>King AA, Debaun MR, Riccardi VM, Gutmann DH. Malignant peripheral nerve sheath tumors in neurofibromatosis 1. Am J Med Genet. 2000;93(5):388–392.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10951462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol. 2009;61(1):1–4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2716546</ArticleId>
            <ArticleId IdType="pubmed">19539839</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grobmyer SR, Reith JD, Shahlaee A, Bush CH, Hochwald SN. Malignant peripheral nerve sheath tumor: molecular pathogenesis and current management considerations. J Surg Onco. 2008;97(4):340–349.</Citation>
        </Reference>
        <Reference>
          <Citation>Suh JS, Abenoza P, Galloway HR, Everson LI, Griffiths HJ. Peripheral (extracranial) nerve tumors: correlation of MR imaging and histologic findings. Radiology. 1992;183(2):341–346.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1561333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wasa J, Nishida Y, Tsukushi S, Shido Y, Sugiura H, Nakashima H, et al.  MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. AJR Am J Roentgenol. 2010;194(6):1568–1574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20489098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>James AW, Shurell E, Singh A, Dry SM, Eilber FC. Malignant peripheral nerve sheath tumor. Surg Oncol Clin. 2016;25(4):789–802.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
